-
Whole Blood circUSP10 for Early NSCLC Diagnosis
2026-09-04
The reference study identified hsa_circ_0003026, termed circUSP10, as an elevated circular RNA in early-stage non-small-cell lung cancer and evaluated its diagnostic potential in whole blood. Its discovery-to-validation workflow connects tissue profiling, RT-qPCR confirmation, blood-based detection, stability testing, and ROC analysis, while also highlighting the need for independent clinical validation.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-04
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central practical implication is that drug evaluation should distinguish proliferative arrest from cell killing and consider their different temporal relationships.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-03
HyperPFU™ high-fidelity DNA polymerase is designed for accurate PCR amplification of long, GC-rich, and otherwise difficult DNA templates. It is suitable for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or sticky-end products.
-
AG-221 (Enasidenib): Reliable AML Assays
2026-09-03
Learn how AG-221 (Enasidenib), SKU B7804, can support genotype-directed acute myeloid leukemia research through IDH2 R140Q inhibition, 2-hydroxyglutarate reduction, and better-controlled assay workflows. The article connects formulation, experimental design, differentiation, viability, and metabolic readouts to practical laboratory decisions.
-
Actinomycin D for mRNA Stability in AML
2026-09-02
Actinomycin D is more than a general transcriptional inhibitor: it can help distinguish altered mRNA production from altered mRNA decay in acute myeloid leukemia models. This guide connects ActD-chase assay design with IGF2BP3–EPOR biology, practical handling, and interpretation limits.
-
Insulin–AMPK Control of PINK1 in Neurons
2026-09-02
This bioRxiv preprint identifies insulin–AMPK signaling as a metabolic switch that controls mitochondrial Pink1 mRNA localization and PINK1 activity in neurons. The findings connect insulin resistance, including an ApoE4-associated in vitro model, with impaired neuronal mitophagy and provide a framework for studying metabolic regulation of mitochondrial quality control.
-
Actinomycin D in BBB mRNA Stability Research
2026-09-01
Actinomycin D can do more than suppress transcription: it can help distinguish mRNA synthesis from decay in blood–brain barrier models. This article translates RBM3–MEF2C findings into a rigorous ActD assay strategy while addressing DNA damage, apoptosis induction, and experimental limitations.
-
Matrine: From Assay Signal to Mechanism
2026-09-01
Matrine is a Sophora-derived alkaloid with anticancer, apoptotic, and anti-inflammatory research applications. This guide converts recent thymoma findings into an evidence-calibrated assay strategy that separates phenotypic activity from causal mechanism.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-08-31
The reference study positions moesin (MSN) as both a circulating indicator of endothelial injury and a mechanistic contributor to vascular barrier dysfunction in sepsis. By combining patient samples, LPS and CLP mouse models, and MSN-silenced human microvascular endothelial cells, the authors connect serum MSN with disease severity, Rock1/myosin light chain signaling, NF-κB activation, inflammation, and hyperpermeability.
-
AG-221 Workflows for IDH2-Mutant AML
2026-08-31
AG-221 (Enasidenib) enables genotype-aware AML experiments that connect 2-hydroxyglutarate reduction with differentiation and metabolic dependency. This practical guide integrates dose-response design, metabolite sampling, CD44-focused validation, and troubleshooting for more interpretable IDH2-mutant leukemia studies.
-
CD38 CAR Binder Structure and Affinity Tuning
2026-08-30
This 2026 iScience study defines how two CD38-targeting CAR binders, RP02 and 028, recognize different structural regions and produce distinct effects on CD38 enzymatic activity. Its structure-guided analysis shows that affinity attenuation with the 028R103G variant can reduce CAR-T fratricide while preserving antitumor cytotoxicity, providing a mechanistic framework for tuning CD38-directed cell therapies.
-
S Tag Peptide: Fusion Tag Workflow Guide
2026-08-29
S Tag Peptide (SKU A6007) supports recombinant protein detection, antibody-based purification workflows, and protein solubility improvement when genetically fused to a target protein. It should be handled as a short-term aqueous or DMSO-compatible reagent and is not appropriate for ethanol-based systems or assumptions of independent enzymatic activity.
-
DiscoveryProbe FDA-Approved Drug Library: SUGCT
2026-08-28
The DiscoveryProbe FDA-approved Drug Library (SKU L1021) is an FDA-approved bioactive compound library containing 2,320 pre-dissolved compounds for screening and drug repositioning. Its chemical diversity provides a practical starting point for testing metabolic hypotheses such as SUGCT inhibition, but the cited SUGCT study does not establish clinical efficacy for any library compound.
-
Mubritinib (TAK 165): From HER2 to Complex I
2026-08-28
Mubritinib (TAK 165) illustrates how a compound first associated with HER2 can acquire a more compelling translational identity as a mitochondrial complex I inhibitor. This thought-leadership perspective connects target biology, albumin binding, assay design, and repurposing strategy for chemotherapy-resistant AML and KSHV-positive primary effusion lymphoma research.
-
SmD2 Acetylation Rewires HCC Splicing and PARP Response
2026-08-27
This 2024 Nature Communications study identifies acetylation-controlled SmD2, a core spliceosome component, as a regulator of BRCA1/FANC cassette exons, DNA-damage responses, and PARP-inhibitor sensitivity in hepatocellular carcinoma. Its findings connect spliceosome regulation with epigenetic therapy and support testing HDAC–PARP inhibitor combinations, while also highlighting important limits for translation beyond the examined HCC models.